Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: Synthesis and pharmacological evaluation of 2-oxopiperazine derivatives

Journal of Medicinal Chemistry

Volumn 44, Issue 15, 2001, Pages 2438-2450

  Kitamura, S ^a   Fukushi, H ^a   Miyawaki, T ^a   Kawamura, M ^a   Konishi, N ^a   Terashita, Z I ^a   Naka, T ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [(4 GUANIDINOBENZOYL)AMINO]ACETYL] 3 [3 [(4 GUANIDINOBENZOYL)AMINO]PROPYL] 2 OXOPIPERAZINYL]ACETIC ACID; 2 OXOPIPERAZINE DERIVATIVE; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; TAK 024; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GUINEA PIG; NONHUMAN; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ANIMALS; BALLOON DILATATION; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; GUANIDINES; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; MALE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035913049     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0004345     Document Type: Article

References (22)

1. Plaque fissuring - The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
3. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von willebrand factor binding to platelets
4. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets
5. The platelet membrane glycoprotein IIb/IIIa complex
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
7. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at Six Months
8. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
9. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions
10. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide
11. Novel non-peptide GPIIb/ IIIa antagonists: Synthesis and biological activities of 2-[4-[2(4-Amidinobenzoylamino)-2-(substituted)acetyl]-3- (2-methoxy-2oxoethyl)-2-oxopiperazinyl]acetic acids
12. 3 antagonists
13. 2protected L-2,3-diaminopropanoic acid
14. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-AspPhe sequence of fibrinogen. A proposal on the nature of the binding interaction between the arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa Receptor
15. 1 and argatroban
16. 2+ on GP IIb-IIIa interactions with integrilin. Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticogulated with citrate
17. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis
18. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
19. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
20. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents. Coronary artery reocculusion after reperfusion with recombinant tissue-type plasminogen activator in dogs
21. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggragtion and macroaggregation formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists